|The European Agency for the Evaluation of Medicinal Products|
|Human Medicines Evaluation Unit|
|London, 3 August, 1998|
|Direct Line +44.171.418.8411|
I am writing to you further to your letter of 24 July, 1998.
I can inform you that after adoption, EMEA opinions are forwarded to the European Commission. Once received by the European Commission, an EMEA opinion is subject to a procedure which results in a binding Commission Decision.
The Commission Service which principally administers this procedure in the Pharmaceuticals Products and Cosmetics Unit of Directorate General III.
I would suggest that you contact directly Mr Patrick Deboyser, Head of Unit (Tel.++32.2.295.41.28 - Fax++32.2.296.15.20)
I hope this information is helpful.
|Head of Human Medicines Evaluation Unit|
|Social Audit Ltd|
|P O Box 111 London NW1 8XG|
|Telephone/Fax 44 (0)171 586 7771|
Dear Professor Bass,Thanks for your fax and for telling me that the CPMP/EMEA opinion has been forwarded to the Pharmaceutical Products and Cosmetics Unit of DGIII
I will get in touch with M Deboyser as you suggest. Thank you for this helpful information.